Gearty SV, Dündar F, Zumbo P, Espinosa-Carrasco G, Shakiba M, Sanchez-Rivera F, Socci ND, Trivedi D, Lowe SW, Lauer P, Mohibullah N, DiLorenzo TP, Viale A, Betel D, Schietinger A. A stem-like autoimmune CD8 T cell population drives type 1 diabetes. Nature 2022 Feb;602(7895):156-161.

Shakiba M, Zumbo P, Dündar F, Espinosa-Carrasco G, Camara S, Sanchez-Rivera FG, Lowe SW, Koche RP, Reuter VP, Socci ND, Whitlock B, Tamzalit F, Huse M, Betel D, Philip M, Schietinger A. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. Journal of Experimental Medicine 2022 Feb 7;219(2):e20201966.

Philip M and Schietinger A. CD8 T cell differentiation and dysfunction in cancer. Nature Reviews Immunology. 2022 Apr;22(4):209-223.

TOX is a critical regulator of tumour-specific T cell differentiation. Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P, Menocal L, Appleby H, Camara S, Zamarin D, Walther T, Snyder A, Femia MR, Comen EA, Wen HY, Hellmann MD, Anandasabapathy N, Liu Y, Altorki NK, Lauer P, Levy O, Glickman MS, Kaye J, Betel D, Philip M, Schietinger A. Nature. 2019 Jul;571(7764):270-274. doi: 10.1038/s41586-019-1324-y. Epub 2019 Jun 17.

Chromatin states define tumour-specific T cell dysfunction and reprogramming. Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, Scott AC, Viale A, Lauer P, Merghoub T, Hellmann MD, Wolchok JD, Leslie CS, Schietinger A. Nature. 2017 May 25;545(7655):452-456. doi: 10.1038/nature22367. Epub 2017 May 17.

Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, Schell TD, Garbi N, Greenberg PD. Immunity. 2016 Aug 16;45(2):389-401. doi: 10.1016/j.immuni.2016.07.011. Epub 2016 Aug 9.

Schietinger A and Greenberg PD. “Tolerance and Exhaustion: Defining Mechanisms of T cell dysfunction.” (2014) Trends in Immunology, 35(2):51-60.

Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, Bindokas V, Bartkowiak T, Lee D, Herrmann A, Piston DW, Pittet MJ, Lin CP, Zal T, and Schreiber H. “Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer.” (2014) Oncoimmunology, 2013 Nov 1;2(11):e26677.

Schietinger A, Delrow J, Basom R, Blattman JN, Greenberg PD. “Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state.” (2012) Science, 335(6069): 723-7.

Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H. “Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase.” (2010) Journal of Experimental Medicine, 207(11): 2469-77.

Schietinger A, Philip M, Schreiber H. “Specificity in Cancer Immunotherapy.” (2008) Seminars in Immunology, 20(5): 276-85.

Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, Schreiber H. “A mutant chaperone converts a wild-type protein into a tumor-specific antigen.” (2006) Science, 314(5797): 304-308;